Botanix Pharmaceuticals Limited (ASX: BOT)
Australia
· Delayed Price · Currency is AUD 0.365
-0.025 (-6.41%)
Dec 20, 2024, 4:10 PM AEST
Botanix Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2016 |
| Operating Revenue | 2.07 | 2.07 | 3.77 | 2.75 | 6.88 | 7.56 | Upgrade
|
| Other Revenue | - | - | - | - | 0.01 | 0.01 | Upgrade
|
| Revenue | 2.07 | 2.07 | 3.77 | 2.75 | 6.89 | 7.57 | Upgrade
|
| Revenue Growth (YoY) | -45.14% | -45.14% | 36.94% | -60.00% | -9.07% | 61.63% | Upgrade
|
| Cost of Revenue | 3.65 | 3.65 | 5.73 | 10.29 | 6.57 | 13.7 | Upgrade
|
| Gross Profit | -1.58 | -1.58 | -1.96 | -7.54 | 0.32 | -6.13 | Upgrade
|
| Selling, General & Admin | 6.91 | 6.91 | 4.41 | 4.28 | 2.62 | 7.35 | Upgrade
|
| Other Operating Expenses | 1.03 | 1.03 | 1.13 | 0.89 | 0.41 | 0.78 | Upgrade
|
| Operating Expenses | 12.41 | 12.41 | 7.17 | 5.65 | 3.7 | 10.56 | Upgrade
|
| Operating Income | -13.99 | -13.99 | -9.13 | -13.19 | -3.38 | -16.69 | Upgrade
|
| Interest Expense | -0.01 | -0.01 | -0.08 | -0.04 | -0.06 | -0.05 | Upgrade
|
| Interest & Investment Income | 0.08 | 0.08 | 0.07 | 0.04 | 0.1 | 0.17 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.06 | 0.06 | -0.01 | 0.02 | -0 | -0.17 | Upgrade
|
| Pretax Income | -13.87 | -13.87 | -9.15 | -13.17 | -3.33 | -16.73 | Upgrade
|
| Net Income | -13.87 | -13.87 | -9.15 | -13.17 | -3.33 | -16.73 | Upgrade
|
| Net Income to Common | -13.87 | -13.87 | -9.15 | -13.17 | -3.33 | -16.73 | Upgrade
|
| Shares Outstanding (Basic) | 1,502 | 1,502 | 1,154 | 973 | 973 | 936 | Upgrade
|
| Shares Outstanding (Diluted) | 1,502 | 1,502 | 1,154 | 973 | 973 | 936 | Upgrade
|
| Shares Change (YoY) | 30.12% | 30.12% | 18.58% | 0.02% | 3.90% | 23.13% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.02 | Upgrade
|
| Free Cash Flow | -8.24 | -8.24 | -12.08 | -11.19 | -2.98 | -17.45 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.02 | Upgrade
|
| Gross Margin | -76.48% | -76.48% | -51.83% | -273.62% | 4.59% | -80.87% | Upgrade
|
| Operating Margin | -676.11% | -676.11% | -241.93% | -478.66% | -49.08% | -220.30% | Upgrade
|
| Profit Margin | -670.20% | -670.20% | -242.66% | -478.10% | -48.41% | -220.90% | Upgrade
|
| Free Cash Flow Margin | -398.17% | -398.17% | -320.27% | -406.24% | -43.22% | -230.38% | Upgrade
|
| EBITDA | -13.92 | -13.92 | -9.11 | -13.17 | -3.36 | -16.67 | Upgrade
|
| EBITDA Margin | - | - | -241.38% | - | -48.84% | -220.14% | Upgrade
|
| D&A For EBITDA | 0.07 | 0.07 | 0.02 | 0.02 | 0.02 | 0.01 | Upgrade
|
| EBIT | -13.99 | -13.99 | -9.13 | -13.19 | -3.38 | -16.69 | Upgrade
|
| EBIT Margin | - | - | -241.93% | - | -49.08% | -220.30% | Upgrade
|
| Revenue as Reported | - | - | - | 2.79 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.